

INDEX

Note: RA stands for rheumatoid arthritis.

Page numbers in *italics* indicate figures.

Page numbers followed by a “t” indicate tables.

- Abatacept (Orencia), 277-289
biochemical composition, 277
clinical efficacy, 279-283, 281-284
 AIM study, 280, 281
 HAQ Disability Index, 282, 283
combination therapy, with MTX, 279-280, 281
contraindications, 277
dosage and administration, 288-289, 288t
half-life, 278
indications for, 179, 277
mechanism of action, 277-278, 278
pharmacology, 278-279
safety, 283-288
 adverse events, overall, 285, 286, 287t
 ASSURE study, 285-288, 287t
 infusion reactions, 285
 neoplasms, 287t, 288
 serious adverse events, 285, 286, 287t
 serious infections, 286-288, 287t
- Access to care, 85-86
- Acetaminophen, 115
 for infusion reactions, 231
 for injection site reactions, 205
- Achilles tendon, 38, 43
- ACR. See *American College of Rheumatology (ACR)*.
- Acute onset, 31
- Acute-phase reactants, 76
- Adalimumab (Humira), 176-178, 244-257. See also *TNF-blocking therapies*.
 for aggressive RA, 111
 binding properties, 200, 245
 biochemical composition, 198
 biologic effects, 199-201, 199t
 clinical efficacy in RA, 246-249, 247-249
 clinical trials
 ARMADA trial, 151, 246, 247, 248
 DEO19 trial, 246-249, 248-249, 256
 ERA trial, 150
 PREMIER trial, 250-251, 252-254
 combination therapy, 92, 163, 214, 245, 246-249, 248-249, 250-251, 252-254
- Adalimumab (Humira) (*continued*)
 in early RA, 249-251, 250
 approval for, 179, 245, 249
 in elderly patients, 251-253
 half-life, 245
 indications and dosing, 198t, 245
 for other inflammatory conditions, 245
 pharmacology, 245-246
 safety in RA, 203-204, 242-243, 254-257, 255t, 294
 antibodies against adalimumab, 255
 autoimmune responses, 214, 255
 congestive heart failure, 255t
 cytopenias, 217
 demyelinating syndromes, 216, 255t
 drug-induced lupus, 255t
 HBV reactivation, 256-257
 hepatotoxicity, 218
 infections, 207-208, 211, 254, 255t, 256
 injection site reactions, 205-206, 254-255
 lymphoma, 212, 255t, 257
 malignancies, 213
 pregnancy and lactation, 218-219
 tuberculosis, 209-210, 255t
 vaccinations, 257
- Adenomatous Polyp Prevention (APC) trial, 125
- Adenomatous Polyp Prevention on VIOXX (APPROVE) trial, 126
- Adenomatous polyps, 50
- Adhesion molecules, 200, 296
- Adult-onset Still's disease (AOSD), 53-54
- Age
 as prognostic factor in RA, 59
 as risk factor for RA, 20
- Aggressive RA, 110-111, 110t
 biologic therapies, effectiveness in, 181
 corticosteroid treatment for, 135-136, 139-140
 DMARDs for, 111, 144, 163, 168, 169
 HLA-DR molecules in, 76-77
- AIM study, 280, 281
- Alefacept (Amevive), 289
- American College of Rheumatology (ACR)
 clinical response criteria, 319-322, 321t
 RA classification (diagnosis) criteria, 67-68, 67t, 95
 remission criteria, 55
 treatment algorithm, 112
 website, 101t
- Amevive (alefacept), 289
- Amitriptyline, 115

Amyloidosis, 50, 59
 ANA. See *Antinuclear antibody (ANA)*.
 Anakinra, 186-192
 for adult-onset Still's disease (AOSD), 54
 adverse events, 189-192, 190
 infections, 190-192
 injection site reactions (ISRs), 189-190, 190
 neutropenia, 190
 for aggressive RA, 111
 clinical efficacy, 187-189, 188
 combination therapy, 163
 with etanercept, 191-192
 with MTX, 188-189, 188
 contraindications, 191
 daily injections, 189, 192
 dosage, 189
 FDA approval of, 187-188
 half-life, 187, 189, 192
 indications for, 179, 187-189
 mechanism of action, 186-187, 187
 practical issues, 192
 safety in RA, 189-190, 190
 Analgesic therapies, 113, 115-116. See also *Pain treatments*.
 Anaphylactic reactions, TNF-blocking therapies, 205, 231-232
 Anemia of chronic disease, 50, 76
 Angiogenesis, 16, 21, 200
 TNF-blocking therapies and, 296
 Ankle involvement in RA, 38
 Ankylosing spondylitis, 197, 198t, 201, 221, 245
 Ansaïd (flurbiprofen), 118t
 Anti-CCP. See *CCP (cyclic citrullinated peptide) antibodies*.
 Anti-tumor necrosis factor (TNF). See *TNF-blocking therapies*.
 Antibodies. See *Autoantibodies; specific antibodies*.
 Anticoagulants, NSAID therapy contraindicated with, 130-131
 Antidepressants, tricyclic, for pain, 115
 Antigen-presenting cell (APC), 275, 276
 Antigens, in RA pathogenesis, 23-24
 Antihistamines, for injection site/infusion reactions, 205, 231
 Antinuclear antibody (ANA), 53, 108, 214, 215, 216
 with adalimumab treatment, 255t
 with etanercept treatment, 243
 APC (Adenomatous Polyp Prevention) trial, 125
 Apoptosis, TNF-blocking agents and, 201
 APPROVE trial, 126
 ARMADA trial, 151, 246, 247, 248
 Arthritis Foundation website, 101t
 Arthritis Society of Canada website, 101t
 Arthrotec (diclofenac), 118t, 120
 Articular surface, 15, 18. See also *Joint involvement in RA*.
 Artificial tear- and saliva-substitutes, 47
 Aspergillosis, 211
 ASPIRE trial, 82, 151, 227-228, 228t, 229, 233
 Aspirin, 118t, 122, 132
 ASSURE study, 285-288, 287t
 Atherosclerosis, 57, 58
 Atlantoaxial (C1-C2) joint involvement, 39
 ATTRACT trial, 151, 223-224, 225t, 226, 233
 Auranofin (oral gold), 146t, 153, 154-155
 Aurothioglucose, 153
 Aurothiomalate, 153
 Autoantibodies. See also *Antinuclear antibody (ANA); CCP (cyclic citrullinated peptide) antibodies; Rheumatoid factor (RF)*.
 double-stranded DNA (dsDNA) antibodies, 214, 215, 216
 endogenous antigens and, 23
 monitoring for, 220
 in pathogenesis of RA, 17, 24, 175-176
 as prognostic factor in RA, 59, 60t
 SS-A (anti-Ro) antibodies, 46
 SS-B (anti-La) antibodies, 46
 TNF inhibitors and, 213-216, 255
 Autoimmune conditions
 B cell role in, 263, 264
 rituximab use for, 263-272
 Azathioprine, 159. See also *Disease-modifying antirheumatic drugs (DMARDs)*.
 for adult-onset Still's disease (AOSD), 54
 adverse events, 147t, 159
 continuation rate for, 145
 contraindicated for pregnancy, 145
 safety monitoring, 147t, 159
 for scleritis and episcleritis, 47
 B-cell targeted therapies, 263-274
 rituximab, 176, 263-272
 clinical efficacy, 265-269, 266, 268, 270
 dosage and administration, 271-272
 indications for, 179, 265
 mechanism of action, 263-264, 267
 safety and tolerability, 268-271
 use in other autoimmune diseases, 272
 therapies under development, 272-273
 anti-BAFF/BLyS (belimumab), 273
 anti-CD20 (ocrelizumab, ofatumumab), 272
 anti-CD22 (epratizumab), 272
 recombinant soluble receptor constructs, 273

- B cells. See also *B-cell targeted therapies*.
activation, 263, 264
in pathogenesis of RA, 17, 22, 24-25, 175-176, 263
role in autoimmune conditions, 263, 264
surface antigens, 263-264, 264
targeting, 263, 264
- BAFF/BLyS, antibody to (belimumab), 273
- Baker cyst, 37
- Belimumab, 273
- Bent-fork deformity, 40, 43
- BeST study, 228-231, 230
disease activity scores in, 322-323
- Bextra. See *Valdecoxib*.
- Biologic therapies, 175-183. See also *B-cell targeted therapies*;
Interleukin (IL)-1 inhibitors; *T-cell co-stimulatory pathway blockade*; *TNF-blocking therapies*.
ACR treatment algorithm, 112, 179
aggressive treatment with, 179-181
cytokine activation, 176, 178, 275
cytokine-directed therapies, 175-183
cytokine inhibition, 176-178, 180-181
effectiveness in aggressive RA, 181
guidelines for use, 179-182
indications for, 178-182
- Bouchard's nodes, 69
- Boutonnière deformity, 34, 35, 40
- British Society of Rheumatology Biologics Register, 208
- Bronchiolitis obliterans, 48, 49
- C-reactive protein (CRP), 76, 321
as prognostic factor, 84, 108, 109
in slowly progressive vs aggressive RA, 110t
- C1-C2 joint involvement, 39
- Cancer risk, 49-50
- Candida*, 256
- Caplan's syndrome, 48
- Capsaicin, topical analgesic, 116
- Cardiovascular (CV) events, 124, 125, 126-127, 132
- Cardiovascular disease (CVD), 57-58, 58
morbidity/mortality reduction by RA therapies, 105
- Caspase-1 (IL-1 converting enzyme), 193-194
- CCP (cyclic citrullinated peptide) antibodies, 17
in diagnosis of RA, 65
laboratory testing, 75
as prognostic factor, 59, 60t, 84, 93, 94t, 109
in psoriatic arthritis, 70
as risk factor for RA, 20
- CD20, 263, 264
monoclonal antibody to. See *Rituximab*.
other antibodies to (ocrelizumab, ofatumumab), 272
- CD22, antibody to (epratizumab), 272
- CD28, 275-276, 276
- CD40, 276
- CD80, 275-276, 276
antibodies to, 289
- CD86, 275-276, 276
antibodies to, 289
- CDAI. See *Clinical Disease Activity Index (CDAI)*.
- Celebrex (celecoxib), 119t, 124-125. See also *COX-1 and COX-2 inhibitors*.
- Celecoxib (Celebrex), 119t, 124-125. See also *COX-1 and COX-2 inhibitors*.
- Celecoxib Long-Term Arthritis Safety Study (CLASS), 125
- Certolizumab pegol, 201, 294
- Cervical involvement in RA, 39-40
- Cervical subluxation, 38
- Cevimeline (Evoxac), 47
- Children, polyarticular juvenile arthritis, 52-53
- Choline magnesium salicylate (Trilisate), 118t, 123
- Chronicity of RA, 13, 106
- Cigarette smoking, as risk factor for RA, 20
- Cimetidine, 128-129
- CLASS (Celecoxib Long-Term Arthritis Safety Study), 125
- Clinical Disease Activity Index (CDAI), 325-326, 325t
- Clinical features of RA, 29-54
cervical involvement, 39-40
deformities, 35, 40, 41-43
demographics and epidemiology, 29, 30t
extra-articular manifestations, 41-50
infectious and malignant complications, 49-50
pulmonary complications, 48-49
rheumatoid nodules, 36, 42-44, 42
rheumatoid vasculitis, 44-46
Sjogren's syndrome, 46-47
joint involvement, 32-35
lower extremity involvement, 37-38
morning stiffness, 32
onset, 29-32
prognostic factors, 59, 60t-61t, 84-85
rheumatoid variants, 51-54
adult-onset Still's disease (AOSD), 53-54
elderly-onset RA, 52
palindromic rheumatism, 51-52
polyarticular juvenile arthritis, 52-53

Clinical features of RA, rheumatoid variants (*continued*)

- undifferentiated polyarthritis, 51
 - symmetric joint distribution, 31
 - upper extremity involvement, 35-36
- Clinical trials and research studies
- AIM study, 280, 281
 - APC trial, 125
 - APPROVE trial, 126
 - ARMADA trial, 151, 246, 247, 248
 - ASPIRE trial, 82, 151, 227-228, 228t, 229, 233
 - ASSURE study, 285-288, 287t
 - ATTRACT trial, 151, 223-224, 225t, 226, 233
 - CLASS study, 125
 - COBRA trial, 89-90, 91, 138, 164-167, 165-166, 169
 - DANCER trial, 267-269, 268
 - DEO19 trial, 246-249, 248-249, 256
 - disease activity measures in, 316-323
 - ERA trial, 82, 150, 179, 240-241, 241-242
 - FinRA-Co trial, 90, 167, 169
 - HERA trial, 153
 - PREMIER trial, 82, 151, 250-251, 252-254
 - PROMPT trial, 84, 151
 - REFLEX trial, 269, 270
 - TEMPO trial, 151, 237-240, 239t
 - TICORA trial, 59-62, 322-323
 - VIGOR trial, 126
- Clinoril (sulindac), 119t
- Co-stimulatory pathways. See *T-cell co-stimulatory pathway blockade*.
- COBRA trial, 89-90, 91, 138, 164-167, 165-166, 169
- Coccidioidomycosis, 211
- Codeine, 115
- Cold packs, 116
- Collagen, type II, antigens, 23
- Combination therapy, 106, 111, 112. See also *specific drugs and agents*.
- vs single therapy, 89-92, 91
- Complement inhibition, 296
- Congestive heart failure (CHF)
- TNF-blocking therapies and, 217
 - adalimumab, 255t
 - etanercept, 243t, 244
 - infliximab, 232t
- Coronary heart disease (CHD), risk of, 57
- Corticosteroids, 135-142. See also *specific corticosteroids*.
- for adult-onset Still's disease (AOSD), 54
 - adverse effects, 136-137, 137t

Corticosteroids (*continued*)

- for aggressive RA, 111
 - as bridge therapy to DMARDs, 136, 170
 - for bronchiolitis obliterans, 49
 - disease-modifying effects of, 138-139, 140
 - in early RA, 137-141, 170
 - for hypersensitivity pneumonitis, 49
 - infections as potential side-effect of, 137
 - for infusion reactions, 231
 - for injection site reactions, 205
 - intraarticular, 138, 140-141
 - intramuscular injection, 108, 110, 138
 - mechanisms of efficacy, 135
 - for palindromic rheumatism, 52
 - pulse therapy, 141, 170
 - for respiratory distress, 40
 - for scleritis and episcleritis, 47
 - for slowly progressive RA, 110
 - steroid-induced osteoporosis, 137
 - steroid toxicity, 136
 - steroid withdrawal syndrome, 136
- Cost of RA, 14, 56-57, 297
- COX-1 and COX-2 inhibitors, 120-132. See also *NSAIDs (nonsteroidal anti-inflammatory drugs)*.
- aspirin, 118t, 122
 - concomitant cardioprotective use of, 122, 125, 132
 - cancer risk and, 50
 - indications for, 121
 - mode of action, 120-121
 - COX-1, 120-121
 - COX-2, 121
 - nonacetylated salicylates, 118t, 123
 - selective COX-2 inhibitors, 119t, 121, 123-127
 - celecoxib (Celebrex), 119t, 124-125
 - rofecoxib, 123, 124, 125-127
 - valdecoxib, 123, 127
 - toxicities, 124, 127-131
 - CV toxicity, 124, 125, 126-127
 - GI toxicity, 121, 123-124, 125, 127-129
 - guidelines to minimize, 128t
- Coxibs. See *COX-1 and COX-2 inhibitors*.
- Creatinine, monitoring in NSAID therapy, 130
- Cricoarytenoid joint involvement in RA, 39-40
- Crohn's disease
- certolizumab pegol for, 201, 294
 - TNF-blocking agents for, 197, 198t, 201, 220, 245
 - autoantibody production and, 213-214

Cryptococcus, 256
 CTLA-4, 275-276, 276
 CTLA-4/Ig fusion protein. See *Abatacept (Orencia)*.
 Cyclic citrullinated peptide (CCP). See *CCP (cyclic citrullinated peptide) antibodies*.
 Cyclooxygenase (COX) inhibition. See *COX-1 and COX-2 inhibitors*.
 Cyclophosphamide, 159. See also *Disease-modifying antirheumatic drugs (DMARDs)*.
 in clinical studies with rituximab, 265-267, 266
 for rheumatoid vasculitis, 45
 for scleritis and episcleritis, 48
 Cyclosporine, 16, 143, 156-157, 275. See also *Disease-modifying antirheumatic drugs (DMARDs)*.
 adverse events, 147t, 156
 combination therapy, 163
 for cutaneous psoriasis, 156
 in early RA, 157
 onset of effective action, 157
 for psoriatic arthritis, 156
 RF titer and, 74
 safety monitoring, 147t, 156-157
 for scleritis and episcleritis, 47
 for Sjogren's syndrome, 47
 toxicities, 147t, 156, 175
 Cytokine-directed therapies, 175-183. See also *Interleukin-1 inhibitors; TNF-blocking therapies*.
 activation of cytokines in RA, 176, 178, 275
 future directions, 295-296
 indications for, 178-182
 inhibition of cytokines, 176-178, 180-181
 TNF α and IL-1 β in rheumatoid joint, 176, 177
 Cytokines. See also *Cytokine-directed therapies*.
 balance of proinflammatory/anti-inflammatory, 176, 178
 clinical features affected by, 25
 corticosteroids and, 135
 cytokine-directed therapies, 175-183
 induction by activated T cells, 275
 induction by TNF α , 200
 mast cell secretion of, 18
 pain and, 111
 in pathogenesis of RA, 18, 22, 23, 25, 176, 178
 Cytomegalovirus, 211
 Cytopenia
 pulse corticosteroid therapy for, 141
 TNF inhibitors and, 217-218, 232t
 Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), 275-276, 276
 DANCER trial, 267-269, 268
 Dapsone, 143
 DAS. See *Disease activity score (DAS)*.
 Daypro (oxaprozin), 119t
 Deformities in RA, 34, 35, 40, 41-43
 bent-fork deformity, 40, 43
 boutonnière deformity, 34, 35, 40
 hallux valgus, 35, 38, 40
 impairment of mobility by, 40
 piano key deformity, 40
 swan neck deformity, 34, 35, 40, 41
 ulnar drift, 34, 35, 40, 42
 zeta deformity, 40, 42
 Demographics of RA, 29, 30t
 Demyelinating syndromes, 216, 243, 255t
 Dendritic cells, in RA pathology, 18, 22
 DEO19 trial, 246-249, 248-249, 256
 Dextromethorphan, 149
 Diagnosis
 algorithm for, 66
 criteria, 65-71
 ACR classification criteria, 67-68, 67t, 95
 anti-CCP positivity, 65
 diagnostic approach, 65, 66
 inflammatory manifestations, 65
 joint involvement/pattern, 32-34, 33, 65
 rheumatoid factor (RF), 65
 rheumatoid nodules, 65
 delays in, 299, 300t
 diagnostic testing/imaging, 73-79
 genetic testing, 76-77
 imaging studies, 77-79
 laboratory tests, 73-76
 differential diagnosis, 68-71
 algorithm for, 66
 based on joint involvement, 32-34, 33
 gout, 69-70
 osteoarthritis, 68-69
 psoriatic arthritis, 70
 reactive arthritis, 70-71
 early RA diagnosis, 66, 81-98
 access to care, 85-86
 challenge of, 94-95
 impact of intervention, 88-92
 prognosis and, 59, 81
 referrals and, 92-94, 93t
 utility of ACR criteria for, 67-68, 95
 window of opportunity, 82-85, 83t

- Diarthrodial joints, 14-15
- Diclofenac (Arthrotec, Voltaren, Voltaren XR), 118t, 120
- Differential diagnosis, 68-71. See also *Diagnosis*.
- Diflunisal (Dolobid), 118t, 123
- DIP (distal interphalangeal) joints
involvement in osteoarthritis, 69
involvement in RA, 33, 34
- Disability, work, 13-14, 57
- Disalcid (salsalate), 118t, 123
- Disease activity measures, 316-326
- Disease activity score (DAS), 322-323, 323t
- Disease-modifying antirheumatic drugs (DMARDs), 105-106, 143-173. See also *specific drugs*.
adverse events, 144, 146t-147t, 208
for aggressive RA, 111, 144, 163, 168
bridge therapy, corticosteroids for, 136
combination therapy, 162-169
for aggressive RA, 111, 163, 168, 169
clinical outcomes, 164-165, 165
in early RA, 164-169, 165-166
monotherapy vs combined therapy, 167-168
radiographic outcomes, 165-166, 166
switch monotherapy vs add-on therapy, 168
continuation rates, 144, 145
contraindications, 145
delays in/time lag to treatment, 300t, 301
drugs included, 143
early intervention, 111, 169-170
benefits of, 89-92, 91, 143-144, 145
effect of delay in, 88-89, 89, 92
impact of, 88-92, 88t
importance of, 81, 84, 92
in early RA, 82-85, 83t, 88-92, 164-169, 165-166
onset of effective action, 136, 143
pneumonia risk and, 49
remission rates and, 56
safety monitoring, 144, 146t-147t
single vs combined therapy, 89-92, 91
for slowly progressive RA, 110, 144
symptom modification by, vs disease progression, 106, 144
toxicities of, 144, 146t-147t
- Distal interphalangeal (DIP) joints, 33, 34, 69
- DMARDs. See *Disease-modifying antirheumatic drugs (DMARDs)*.
- DNA, antibodies to double-stranded (dsDNA), 214, 215, 216, 243
dna-j, 23
- Dolobid (diflunisal), 118t, 123
- Double-stranded DNA (dsDNA) antibodies, 214, 215, 216, 243
- Doxycycline, 161-162
- Dry eyes, 46-47
- Dry mouth, 46-47
- Early arthritis clinic, 107, 297-327
delays in diagnosis, referral, and treatment, 299-301, 300t
disease activity measures, 316-326
ACR responses, 319-322, 321t
Clinical Disease Activity Index (CDAI), 325-326, 325t
clinical practice measures, 323-326
clinical trial measures, 316-323
disease activity score (DAS), 322-323, 323t, 327t
Global Arthritis Score (GAS), 324t, 326, 327t
Health Assessment Questionnaire (HAQ), 320t, 323, 324
Simplified Disease Activity Index (SDAI), 325, 325t
early arthritis check list, 310t
early arthritis referral form, 314t-315t
early arthritis status in America, 301-303
facilitating early RA referrals, 301-302, 303-309
benefits of, 304t
key elements, 303-305
referral rules, 93t, 107-108, 308-309
screening requirements, 305-308, 306t-307t
practice remodeling to facilitate referrals, 309-316
dedicated early arthritis clinic, 311
early arthritis referral form, 314t-315t
early arthritis screening clinic, 311
internet screening algorithms, 313-316
physician-to-physician expedited consultation request, 310
prescreening of referrals, 312, 314t-315t
public relations programs, 313
rapid screening clinics, 311-312
telephone screening, 312-313
rationale for, 297-299, 298t
resource tools, 316
early arthritis check list, 310t
early arthritis referral form, 314t-315t
modified Health Assessment Questionnaire, 320t
sample Dear Dr. letter, 317t
66 joint count, 318t
28 joint count, 319t
statistics on, 302-303
- Early arthritis patients, progression to RA, 29, 84-85, 108, 297
- Early inflammatory arthritis (EIA), 297-299
- Early RA. See also *Early arthritis clinic*.
benefits of early diagnosis, 81, 298, 298t
benefits of early treatment, 83-85, 83, 88-92, 88t, 89, 91, 143-144, 145, 298-299, 298t

Early RA (*continued*)
 CCP antibodies in, 75
 check list, 310t
 definition of, 82-83
 diagnosis, 81-98
 access to care, 85-86
 algorithm, 66
 benefits of early diagnosis, 81, 298, 298t
 challenge of early diagnosis, 94-95
 delays in, 299, 300t
 impact of intervention, 88-92, 88t, 89, 91
 referrals, 92-94, 93t
 utility of ACR criteria for, 67-68
 window of opportunity, 82-85, 83t
 disease activity measures, 316-326
 ACR responses, 319-322, 321t
 Clinical Disease Activity Index (CDAI), 325-326, 325t
 disease activity score (DAS), 322-323, 323t, 327t
 Global Arthritis Score (GAS), 324t, 326, 327t
 Health Assessment Questionnaire (HAQ), 320t, 323, 324
 Simplified Disease Activity Index (SDAI), 325, 325t
 ERA trial, 82, 150, 179, 240-241, 241-242
 joint damage in, 82, 106
 late early RA (LERA), 83t
 pharmacotherapy in, 105-114
 corticosteroids, 137-141
 cyclosporine, 157
 DMARDs, 82-85, 83t, 88-92
 DMARDs, combination therapy, 164-169, 165-166
 gold salts, 154-155
 hydroxychloroquine (HCQ), 153, 169
 leflunomide, 161
 methotrexate (MTX), 150-152, 164-168, 165-166, 169
 minocycline, 161-162
 NSAIDs, 120
 sulfasalazine (SSZ), 155-156
 referrals, 301-302, 303-309, 304t
 RF seronegativity in, 73
 TNF inhibitors in, 170, 179, 197, 198, 198t, 201
 adalimumab, 179, 245, 249-251, 250
 etanercept, 179, 240-241, 241-242
 infliximab (Remicade), 179, 226-231
 very early RA (VERA), 83-84, 83t
 window of opportunity in, 82-85, 83t
 Early RA (ERA) trial, 82, 150, 179, 240-241, 241-242
 Early treatment of RA, 105-114. See also *Early arthritis clinic*.
 Easprin (aspirin), 118t
 Ecotrin (aspirin), 118t
 Education
 patient, 99-101, 101t, 105
 primary care community, 304-305
 EIA (early inflammatory arthritis), 297-299
 Elderly-onset RA, 52
 Elderly patients, use of adalimumab in, 251-253
 Employment
 vocational rehabilitation, 103
 work disability, 13-14, 57
 Enbrel (etanercept), 234-244. See also *TNF-blocking therapies*.
 clinical efficacy in RA, 235-240, 237-238, 239t
 indications and dosing, 179-180, 198t, 234
 pharmacology, 235
 safety in RA, 242-244, 243t
 Endothelial cell activation, 16, 18, 21, 22
 Environmental exposures, 31
 Eosinophilia, 50
 Epidemiology of RA, 29, 30t
 Episcleritis, 47-48
 Epratizumab, 272
 Epstein-Barr virus, 20
 ERA trial, 82, 150, 179, 240-241, 241-242
 Erosions. See *Radiographic erosions*.
 Erythema, as clinical sign, 32, 65
 Erythrocyte sedimentation rate (ESR), 76, 108, 109, 321
 in slowly progressive vs aggressive RA, 110t
 ESR. See *Erythrocyte sedimentation rate (ESR)*.
 Etanercept (Enbrel), 178, 234-244. See also *TNF-blocking therapies*.
 for aggressive RA, 111
 approval for RA, 234
 binding properties, 200, 235
 biochemical composition, 198
 biologic effects, 199-201, 199t
 clinical efficacy in RA, 235-240, 237-238, 239t
 clinical trials
 ERA trial, 150, 240-241, 241-242
 etanercept and MTX double-blind trial, 236-237, 237-238
 TEMPO trial, 151, 237-240, 239t
 combination therapy, 151, 163, 243
 with anakinra, 191-192
 with anakinra, contraindication for, 243
 with MTX, 236-240, 237-238, 239t
 with SSZ, 243
 contraindications, 234, 243
 durability, 203, 204, 236

- Etanercept (Enbrel) (*continued*)
 in early RA, 179, 240-241, 241-242
 half-life, 235
 indications and dosing, 179-180, 198t, 234
 p75 receptor and, 201
 pharmacology, 235
 quality-of-life indication, 179
 safety in RA, 242-244, 243t
 autoimmune responses, 213
 congestive heart failure, 243t, 244
 cytopenias, 217
 demyelinating syndromes, 216
 drug-induced lupus, 214-256, 215t, 243, 243t
 hepatotoxicity, 218
 infections, 208, 242-243, 243t
 injection site reactions, 205-206, 205, 242
 lymphoma, 243t, 244
 pneumonia, 243t
 pregnancy and lactation, 218-219
 tuberculosis, 243-244, 243t
- Etiology of RA, 19-20
- Etodolac (Lodine), 118t, 120, 123
- Etodolac SR (Lodine XL), 118t
- Etoricoxib, 123
- Evoxic (cevimeline), 47
- Exercise, 102-103, 105
- Extensor tendon rupture, 34
- Extra-articular manifestations of RA, 41-50
 infectious and malignant complications, 49-50
 mortality risk and, 59
 as prognostic factor, 109
 pulmonary complications, 48-49
 rheumatoid nodules, 36, 42-44, 42
 rheumatoid vasculitis, 44-46
 Sjogren's syndrome, 46-47
 in slowly progressive vs aggressive RA, 110t
- Extracellular matrix, 18, 22
- Family studies. See *Genetic factors in RA*.
- Feldene (piroxican), 119t
- Felty's syndrome, 50, 59
- Female gender, as risk factor for RA, 20, 31
- Fibroblasts, in RA pathology, 18
- Fibrosing alveolitis (interstitial lung disease), 48-49
- FinRA-Co trial, 90, 167, 169
- Flurbiprofen (Ansaid), 118t
- Folate, concomitant with MTX treatment, 148-149
- Follow-up and reassessment of treatment, 109, 111, 112
- Foot involvement in RA, 35, 38, 40
- GAS. See *Global Arthritis Score (GAS)*.
- Gender, as risk factor for RA, 20, 31, 84
- Genetic factors in RA, 20-21, 55
- Genetic testing (HLA genotyping), 76-77
- German Society of Rheumatology Biologics Registry, 208
- Global Arthritis Score (GAS), 324t, 326, 327t
- Gold salts, 106, 153-155. See also *Disease-modifying antirheumatic drugs (DMARDs)*.
 adverse events, 146t
 continuation rates, 145
 in early RA, 154-155
 hypersensitivity pneumonitis and, 48
 intramuscular (IM) gold, 154
 oral (Auranofin), 146t, 153, 154-155
 for palindromic rheumatism, 52
 parenteral, 146t, 153
 for rheumatoid nodules, 44
 safety monitoring, 146t, 154
- Golimumab, 294
- Gout, differential diagnosis of, 69-70
- Granulocyte-macrophage colony-stimulating factor (GM-CSF), 23, 25
- Guillian-Barre syndrome, 216
- H₂-blockers, for NSAID side effects, 128-129
- HACAs (human antichimeric antibodies), 223, 232-233
- Hallux valgus deformity, 35, 38, 40
- HBV (hepatitis B virus), 234, 256-257
- HCQ. See *Hydroxychloroquine (HCQ)*.
- Health Assessment Questionnaire (HAQ), 323, 324
 abatacept efficacy, 282, 283
 cost of RA correlated with, 14
 functional disability and, 14
 modified HAQ, 320t
 TNF-inhibitor use, 179
- Heat packs, 116
- Heat shock proteins, 23
- Heberden's nodes, 69
- Hematologic complications of RA, 50
- Hemolytic anemia, 50
- Hench, Philip, 135
- Hepatitis B virus (HBV), 234, 256-257
- Hepatotoxicity of TNF-blocking therapies, 218, 232t, 233-234
- HERA (Hydroxychloroquine in Early Rheumatoid Arthritis) trial, 153

Herpes zoster, TNF inhibitors and, 211, 256

Hip involvement in RA, 37-38

Histamine, mast cell secretion of, 18

Histoplasma, 256

Histoplasmosis, 211, 232t, 255t

HLA-DR molecules, 16-17, 20-21, 23, 76-77

correlation with aggressive RA, 76-77

genetic association in RA, 21

as risk factor for RA, 21

shared epitopes, 21, 24, 75

as prognostic factor, 61t, 77, 109

testing/genotyping, 76-77

Hodgkin's lymphoma, 212

Human antichimeric antibodies (HACAs), 223, 232-233

Humira (adalimumab), 176-178, 244-257. See also *TNF-blocking therapies*.

for aggressive RA, 111

binding properties, 200, 245

biochemical composition, 198

biologic effects, 199-201, 199t

clinical efficacy in RA, 246-249, 247-249

clinical trials

ARMADA trial, 151, 246, 247, 248

DEO19 trial, 246-249, 248-249, 256

ERA trial, 150

PREMIER trial, 250-251, 252-254

combination therapy, 92, 163, 214, 245, 246-249, 248-249, 250-251, 252-254

in early RA, 249-251, 250

approval for, 179, 245, 249

in elderly patients, 251-253

half-life, 245

indications and dosing, 198t, 245

for other inflammatory conditions, 245

pharmacology, 245-246

safety in RA, 203-204, 242-243, 254-257, 255t, 294

antibodies against adalimumab, 255

autoimmune responses, 214, 255

congestive heart failure, 255t

cytopenias, 217

demyelinating syndromes, 216, 255t

drug-induced lupus, 255t

HBV reactivation, 256-257

hepatotoxicity, 218

infections, 207-208, 211, 254, 255t, 256

injection site reactions, 205-206, 254-255

lymphoma, 212, 255t, 257

Humira (adalimumab), safety in RA (*continued*)

malignancies, 213

pregnancy and lactation, 218-219

tuberculosis, 209-210, 255t

vaccinations, 257

Hydrocodone, 115

Hydroxychloroquine (HCQ), 106, 152-153. See also *Disease-modifying antirheumatic drugs (DMARDs)*.

for adult-onset Still's disease (AOSD), 54

adverse events, 146t, 152-153

combination therapy, 163, 167-168

continuation rate, 145

in early RA, 153, 169

safety monitoring, 146t, 153

for slowly progressive RA, 110, 152

Hypergammaglobulinemia, 76, 175

Hypersensitivity pneumonitis, 48-49, 149

Hypersensitivity reaction, autoantibodies and, 213-214

Hypertension

COX-2 inhibitors and, 124, 126, 127

cyclosporine and, 156

Hypoalbuminemia, 76

Ibuprofen (Motrin), 118t, 120, 122

ICE (IL-1 converting enzyme), 193-194

ICOS, 276, 289

IDEC-114, 289

IL-1. See *Interleukin (IL)-1*.

Imaging studies, 77-79

magnetic resonance imaging (MRI), 78

plain radiography, 77-78

ultrasonography, 78-79

Immobilization, 102

Immunogenetics, 20-21

Immunoglobulins, 17, 24. See also *Rheumatoid factor (RF)*.

Immunopathogenesis of RA, 21-25, 22

humoral hyperactivity, 175-176

Immunosuppressive drugs, 49, 106, 156-157. See also *Cyclosporine*.

Incidence rates of RA, 29, 30t

Indocin (indomethacin), 119t

Indocin-SR (indomethacin-SR), 119t

Indomethacin (Indocin), 119t

Indomethacin-SR (Indocin-SR), 119t

Infections

anakinra and, 190-192

as complication of RA, 49, 206

Infections (*continued*)

- mortality due to, 57
 - opportunistic
 - adalimumab and, 255t
 - infliximab and, 232t, 233
 - TNF inhibitors and, 211
 - rituximab and, 270-271
 - serious
 - abatacept and, 286-288, 287t
 - adalimumab and, 256
 - infliximab and, 208, 233
 - in RA patients, 207
 - TNF inhibitors and, 207-208
 - TNF inhibitors and, 206-208
- Inflammation, 13, 25. See also *Clinical features of RA; Cytokines; Joint involvement in RA.*
- inflammatory pain, 111-113
 - joint swelling as measure of, 32
 - morning stiffness as measure of, 32
 - mortality due to effects of, 57

Infliximab (Remicade), 178, 220-234. See also *TNF-blocking therapies.*

- for aggressive RA, 111
- approved uses
 - Crohn's disease, 220
 - early RA, 179
 - other inflammatory conditions, 221
 - RA, 221
- binding properties, 200, 222
- biochemical composition, 198
- biologic effects, 199-201, 199t
- clinical efficacy in RA, 222-224, 225t, 226
- clinical trials and research studies
 - ASPIRE trial, 82, 151, 227-228, 228t, 229
 - ATTRACT trial, 151, 223-224, 225t, 226
 - BeST study, 228-231, 230
- combination therapy, 151, 163, 168, 223-231, 225t, 226
- contraindications, 222
- in early RA, 179, 226-231
- half-life, 222
- hypersensitivity reaction, 213-214
- indications and dosing, 179, 198t, 221-222
- pharmacology, 222
- quality-of-life indication, 179
- safety in RA, 231-234, 232t
 - anaphylactic reactions, 231-232
 - autoimmune responses, 213-214

Infliximab (Remicade), safety in RA (*continued*)

- congestive heart failure (CHF), 217, 232t
 - cytopenias, 217, 232t
 - demyelinating syndromes, 216
 - HBV reactivation, 234
 - hepatotoxicity, 218, 232t, 233-234
 - infusion reactions, 204-205, 231-233
 - malignancies/lymphoma, 213, 232t, 233
 - opportunistic infections, 232t
 - pregnancy and lactation, 218-219
 - serious infections, 208, 233
 - tuberculosis, 209, 210, 232t
- Infusion reactions
- abatacept and, 285
 - infliximab and, 204-205, 231-233
 - treatment/control of, 205, 231
 - rituximab and, 269-270
- Injection site reactions (ISRs)
- anakinra and, 189-190, 190
 - etanercept and, 205-206, 205
- Interferon- α , 157
- Interferon-gamma (IFN γ), 25
- Interleukin (IL)-1, 23, 25, 185-186. See also *Interleukin (IL)-1 inhibitors.*
- biologic activities, 185
 - cell activation and, 176
 - correlation with RA severity, 185
 - induction relationships, 185-186, 200
 - mononuclear cell migration and, 25
 - in rheumatoid joint, 176, 177
 - synergistic effect with TNF, 186
- Interleukin (IL)-1 inhibitors, 185-195
- agents in development, 192-194
 - IL-1 converting enzyme (ICE, caspase-1), 193-194
 - IL-1 Trap, 193
 - IL-1Ra gene therapy, 194
 - soluble type I IL-1 receptor (sIL-1R1), 192-193
 - anakinra (IL-1Ra), 186-192, 187
 - blockage of cellular activation, 187
 - clinical efficacy, 187-189, 188
 - infection and, 190-192
 - practical issues, 192
 - safety in RA, 189-190, 190
 - transmembrane signaling and, 186-187, 187
- Interleukin (IL)-2, 25, 157
- Interleukin (IL)-3, 18
- Interleukin (IL)-4, 18

- Interleukin (IL)-6, 23, 25, 293
 blocking therapy, 177, 293
 induction by TNF α , 200
- Interleukin (IL)-8, 23, 25, 295
 antibodies/antagonists to, 295-296
- Interleukin (IL)-10, 23, 25
- Interleukin (IL)-15, 178
 monoclonal antibody to, 295
- Interleukin (IL)-17, 178, 289, 295
- Interleukin (IL)-18, 295
- Interstitial lung disease, 48-49
- Intraarticular corticosteroids, 138, 140-141
- Intramuscular corticosteroids, 108, 110, 138
- Intramuscular (IM) gold, 154
- Isoniazid (INH), 211
- Joint involvement in RA, 32-35, 33. See also *Deformities in RA*;
Radiographic erosions; specific joints.
 differential diagnosis based on, 32-34, 33
 early RA, joint damage in, 82, 106
 joints not typically affected, 33-34
 number of joints involved, 60t, 109
 66 joint count, 318t
 28 joint count, 319t
 pain, 32
 as prognostic factor, 59, 60t
 subluxation of joints, 39, 40
 swelling, 32, 34
 as prognostic factor, 59, 84
 in slowly progressive vs aggressive RA, 110t
 swollen joint count (SJC), 319, 321t
 symmetric distribution of, 31, 65
 tender joint count (TJC), 319, 321t
- Juvenile arthritis, TNF-blocking therapies approved for, 197, 198t, 201
- Keratoconjunctivitis sicca. See *Sjogren's syndrome*.
- Ketoprofen (Orudis), 119t
- Ketoprofen-SR (Oruvail), 119t
- Knee joint involvement in RA, 33, 37
- Laboratory tests, 73-76
 acute-phase reactants, 76
 CCP antibodies, 75
 other abnormalities, 76
 rheumatoid factor (RF), 73-74
 synovial fluid analysis, 75-76
- Lactation, TNF-blocking therapies and, 218-219
- Lansoprazole, for NSAID side effects, 129
- Leflunomide, 160-161. See also *Disease-modifying antirheumatic drugs (DMARDs)*.
 adverse events, 147t, 160
 for aggressive RA, 111
 combination therapy, 163
 contraindications, 145, 161
 in early RA, 161
 safety monitoring, 147t
 toxicities, 147t, 160-161
- Leukocyte function-associated antigen (LFA)-1, 23
- Leukocytes, infiltration into synovial capsule, 16
- Leukopenia, TNF-blocking therapies and, 217
- Leukotrienes, 135
- Listeria*, 256
- Listeriosis, 211
- Lodine (etodolac), 118t, 120, 123
- Lodine XL (etodolac SR), 118t
- Lower extremity
 involvement in gout, 69
 involvement in RA, 37-38
- Lumiracoxib, 123
- Lung cancers, 30
- Lupus, drug-induced, TNF inhibitors and, 214-216, 215t, 243, 243t, 255t
- Lymphocytes, 17, 19
- Lymphoid follicles, 17
- Lymphoma, 49, 57, 212
 TNF inhibitors and, 212-213
 adalimumab, 255t, 257
 etanercept, 243t
 infliximab, 232t, 244
- Macrophages, in RA pathogenesis, 20, 22, 23
- Magnetic resonance imaging (MRI), 78
- Major histocompatibility complex (MHC). See *MHC*.
- Malignancies
 abatacept and, 287t, 288
 as complication of RA, 49-50
 in RA, mortality due to, 57, 58
 TNF inhibitors and, 212-213, 233
- Management of RA. See *Treatment of RA*.
- Mast cells, in RA pathology, 17-18, 22
- MCP (metacarpophalangeal) joints, 32, 33
- MCP squeeze, 32, 95, 108
- as predictive factor, 94, 94t

- Meclofenamate (Meclomen), 119t
 Meclomen (meclofenamate), 119t
 MedicineNet.com, 101t
 Meloxicam (Mobic), 119t, 123
 Metabolic syndrome, 58
 Metacarpophalangeal (MCP) joints, 32, 33
 Metalloproteinase (MMP) inhibitors, 161
 Metatarsophalangeal (MTP) joints, 33, 38
 Methotrexate (MTX), 106, 144, 145-152. See also *Disease-modifying antirheumatic drugs (DMARDs)*.
 for adult-onset Still's disease (AOSD), 54
 adverse events, 146t
 for aggressive RA, 111, 163
 benefits for disability, morbidity, and mortality, 149-150
 clinical trials
 ARMADA, 151, 246, 247, 248
 ASPIRE, 82, 151, 227-228, 228t, 229
 ATTRACT, 151, 223-224, 225t, 226
 COBRA, 89-90, 91, 138, 164-167, 165-166, 169
 ERA, 82, 150, 179, 240-241, 241-242
 PREMIER, 82, 151, 250-251, 252-254
 PROMPT, 84, 151
 TEMPO, 151, 237-240, 239t
 combination therapy, 92, 111, 150-152, 163-168
 with abatacept, 279-280, 281
 with adalimumab, 214, 246-249, 248-249, 250-251, 252-254
 with anakinra (IL-1Ra), 188-189, 188
 in early RA, 164-168, 165-166
 with etanercept, 236-240, 237-238, 239t
 with infliximab, 223-231
 monotherapy vs, 167-168
 MTX as anchor drug in, 163, 169, 170
 with rituximab, 265-267, 266, 269, 270, 271
 continuation rate, 145
 contraindicated for pregnancy, 145, 148
 early aggressive use of, 169
 in early RA, 150-152, 169
 combination therapy, 164-168, 165-166
 folate, concomitant daily, 148-149
 “MTX lung” (hypersensitivity pneumonitis), 149
 “MTX nodulosis,” 44
 onset of effective action, 148
 for rheumatoid nodules, 44
 safety monitoring, 146t, 148
 for slowly progressive RA, 110
 toxicities, 146t, 148, 149
 management of, 149
 trial studies, 82, 151
- Methyl salicylate, topical, 116
 Methylprednisolone, intravenous, 141
 MHC (major histocompatibility complex), 16-17
 as antigens, 23
 biologic therapies and, 175
 Class II (HLA-DR) molecules, 16-17, 20-21
 T cell activation and, 275, 276
 Minocycline, 144, 161-162. See also *Disease-modifying antirheumatic drugs (DMARDs)*.
 Misoprostol, 129
 Mobic (meloxicam), 119t, 123
 Mononuclear cells, in RA pathogenesis, 2522
 Morning stiffness, 32, 94t, 108
 Mortality from RA, 57-58, 58, 105
 Motrin (ibuprofen), 118t, 120, 122
 MRI (magnetic resonance imaging), 78
 MTP (metatarsophalangeal) joints, 33, 38
 MTX. See *Methotrexate (MTX)*.
 Multiple sclerosis, 216
Mycobacteria, 20, 233, 256
 M avium intracellulare, 211
 M kansasii, 211
 M marianum, 211
 Mycophenolate, 143
Mycoplasma, 20
- Nabumetone (Relafen), 119t, 123
 Naprosyn (naproxen), 119t
 Naproxen (Naprosyn), 119t
 Narcotics, for pain, 115-116
 National Institutes of Health (NIH) website, 101t
 Neck pain, 39
 Neoplasia. See also *Malignancies*.
 abatacept and, 287t, 288
 TNF inhibitors and, 212-213
 Nerve root impingement, 39
 Neuropathies, 34, 45
 Neutropenia, 217
 New therapies under development, 293-296
 future directions, 295-296
 IL-6 blocking therapy, 293
 TNF inhibitors, 294-295
 NF-κB (nuclear factor kappa B), 294
Nocardia, 211, 256
 Nodules. See *Rheumatoid nodules*.
 Non-Hodgkin's lymphoma, 49, 212
 Nonsteroidal anti-inflammatory drugs (NSAIDs). See *NSAIDs*.

- Nonacetylated salicylates, 118t, 123
- Nonpharmacologic treatment of RA, 99-103, 105
 - patient education, 99-101, 101t
 - physical and occupational therapy, 101-102
 - rest and exercise, 102-103
 - vocational rehabilitation, 103
- NSAIDs (nonsteroidal anti-inflammatory drugs), 115, 117-120, 118t-119t. See also *COX-1 and COX-2 inhibitors*.
 - for adult-onset Still's disease (AOSD), 53-54
 - for aggressive RA, 111
 - analgesic and anti-inflammatory effects of, 117, 120-121
 - antiplatelet activity, 121, 122
 - aspirin, 118t, 122
 - concomitant cardioprotective use of, 132
 - cancer risk and, 50
 - comparison of, 118t-119t
 - contraindications, 117
 - dosages, 117, 118t-119t
 - in early RA, 120
 - nonacetylated salicylates, 118t, 123
 - onset of effective action, 117-120
 - for slowly progressive RA, 110
 - toxicities, 127-131
 - guidelines to minimize, 128t
 - high-risk individuals, 128t, 129, 132
 - unanswered questions about, 131-132
- Occupational therapy, 101-102
- Ocrelizumab, 272
- Ocular manifestations in RA
 - episcleritis and scleritis, 47-48
 - Sjogren's syndrome, 46-47
- Ofatumumab, 272
- Olecranon bursitis, 34-35
- Olecranon nodule, 34, 36, 42-43
- Oligoclonal T-cell expansion, 23-24
- Omeprazole, 129
- Onset of RA, 29-32
- Opportunistic infections, TNF inhibitors and, 211
 - adalimumab, 255t
 - infliximab, 232t, 233
- Orencia. See *Abatacept (Orencia)*.
- Orudis (ketoprofen), 119t
- Oruvail (ketoprofen-SR), 119t
- Osteoarthritis, differential diagnosis of, 68-69
- Osteoporosis, steroid-induced, 137
- Outcomes in RA, 55-64
 - disability and cost of disease, 56-57, 297
 - measurement (Tight Control of RA trial), 59-62
 - mortality, 57-58, 58
 - prognostic factors, 59, 60
 - remission, 55-56, 56
- Oxaprozin (Daypro), 119t
- Oxycodone, 115
- p38 MAP kinases, 294
- p55 receptor, 199
- p75 receptor, 199, 201
- Pain, 32, 113-115. See also *Pain treatments*.
 - inflammatory vs mechanical, 111-113
- Pain treatments, 113, 115-133
 - analgesic therapies, 115-116
 - COX-1 and COX-2 inhibitors, 120-132
 - aspirin, 118t, 122
 - nonacetylated salicylates, 118t, 123
 - selective COX-2 inhibitors, 119t, 121, 123-127
 - mechanical pain, treatments for, 115
 - narcotics, 115-116
 - NSAIDs, 115, 117-120, 118t-119t
 - in early RA, 120
 - toxicity, 127-131, 128t
 - unanswered questions about, 131-132
 - topical analgesia, 116
- Palindromic rheumatism, 51-52
- Pannus, 18
- Paracoxib, 127
- Pathology of RA, 14-19, 21-25, 22
- Patient education, 99-101, 101t, 105
- Penicillamine (PCM), 106, 158. See also *Disease-modifying antirheumatic drugs (DMARDs)*.
 - adverse events, 147t, 158
 - continuation rate, 145
 - hypersensitivity pneumonitis and, 48
 - onset of effective action, 158
 - for rheumatoid nodules, 44
 - safety monitoring, 147t
 - for scleroderma, 158
- Pericardial tamponade, 141
- Periosteum, nodules in, 44
- Peripheral eosinophilia, 50, 76
- Pharmacotherapy, 105-114. See also *specific drugs and treatments*.
 - disease/risk stratification (classification), 109-113, 110t
 - follow-up and reassessment, 109, 111, 112

Pharmacotherapy (*continued*)

- initial choice of therapy, 92, 106, 108-109
- as new paradigm for early RA, 105-114

Physical therapy, 101-102, 105

Piano key deformity, 40

Pilocarpine (Salagen), 47

PIP (proximal interphalangeal) joints

- involvement in osteoarthritis, 69
- involvement in RA, 32, 33, 34

Piroxican (Feldene), 119t

Plasma cells, immunoglobulin secretion, 24

Platelet aggregation, 18

- aspirin and, 122
- COX-1 and, 121, 130
- COX inhibitors and, 122, 124, 130-131

Pleural effusions, 48

Pleurisy, 48

Pleuritis, 48

Pneumocystis, 211, 256

Pneumonia, 49, 243t

Pneumonitis, hypersensitivity, 48-49, 149

Polyarthralgia, 51

Polyarthritis, 51

Polyarticular juvenile arthritis, 52-53

Polyethylene glycol (PEG), 294

Popliteal cysts, 37

Posterior tibialis tendonitis or rupture, 38

PPD (tuberculin skin test), 210-211, 220

Predictive factors. See *Prognostic factors*.

Predictive scores, 84-85, 86-87

Prednisolone, 135, 138-139. See also *Corticosteroids*; *Prednisone*.

- COBRA trial, 164-167, 165-166

Prednisone, 135. See also *Corticosteroids*; *Prednisolone*.

- combination therapy with MTX and SSZ, 228-231, 230
- in early RA, 139-140, 140
- high-dose, 139-140
- COBRA trial, 89-90, 91, 138

low-dose

- disease-modifying effects of, 138-139, 140
- for established RA, 135
- for new-onset joint symptoms, 135
- for slowly progressing RA, 135
- for respiratory distress, 40
- for rheumatoid vasculitis, 45

Pregnancy

- contraindicated agents
- azathioprine, 144

Pregnancy (*continued*)

- leflunomide, 144, 161
- methotrexate (MTX), 144, 148
- TNF-blocking therapies and, 218-219
- PREMIER trial, 82, 151, 250-251, 252-254
- Primary care physicians (PCPs), 85-86. See also *Referrals*; *Rheumatologists*.
- early RA patients and, 94-96
- early referrals and, 107-108
- first evaluation of potential RA patient, 107
- interactions with rheumatologist, 111, 112
- Prognostic factors, 59, 60t-61t, 84-85, 93-94, 94t, 109
- Progressive multifocal leukoencephalopathy (PML), 270-271
- PROMPT trial, 84, 151

Propoxyphene, 115

Prostacyclin, 121

Prostaglandins, 111, 117

- corticosteroids and, 135
- COX inhibitors and, 120, 121, 127-128

Proton pump inhibitors, 129

Proximal interphalangeal (PIP) joints

- involvement in osteoarthritis, 69
- involvement in RA, 32, 33, 34

Psoriasis

- abatacept for, 279
- alefacept (Amevive) for, 289
- TNF-blocking therapies for, 197, 201, 234

Psoriatic arthritis

- cyclosporine for, 156
- differential diagnosis of, 70
- TNF-blocking therapies for, 197, 198t, 201, 221, 234, 245

Public relations programs, 313

Pulmonary complications in RA, 48-49

Pulmonary nodules, 48

Pulse corticosteroid therapy, 141, 170

Purpura, 45

RA. See *Rheumatoid arthritis (RA)*.

Radiculopathy, 39

Radiographic erosions, 18

- in diagnosis of RA, 66, 67t, 77-78, 95
- in early RA, 82
- as prognostic factor, 77-78, 93, 94t
- serum RF and, 74
- in slowly progressive vs aggressive RA, 110t

Radiography, 77-78

Ranitidine, 128-129

Reactive arthritis, differential diagnosis of, 70-71

Referrals, 92-94, 107-108
 access issues, 88
 early referrals, 107-108
 benefits of, 303, 304t
 delays in, 299-301, 300t
 rules for, 93t, 107-108
 facilitated referrals, 301-302, 303-309
 key elements, 303-305
 referral rules, 93t, 107-108, 308-309
 screening requirements, 305-308, 306t-307t
 practice remodeling to facilitate, 309-316, 310t
 early arthritis clinics and screening, 311
 early arthritis referral form, 314t-315t
 internet screening algorithms, 313-316
 physician-to-physician expedited consultation request, 310
 prescreening, 312, 314t-315t
 public relations programs, 313
 rapid screening clinics, 311-312
 telephone screening, 312-313

REFLEX trial, 269, 270

Relafen (nabumetone), 119t, 123

Remicade (infliximab), 220-234. See also *TNF-blocking therapies*.
 approved uses, 179, 220, 221
 clinical efficacy in RA, 222-224, 225t, 226
 indications and dosing, 179, 198t, 221-222
 pharmacology, 222
 safety in RA, 231-234, 232t
 use in early RA, 179, 226-231

Remission, 55-56, 56

Renal disease, mortality from, 58, 59

Renal insufficiency, cyclosporine and, 156-157

Renal involvement in RA, 46

Renal toxicity, due to NSAID therapy, 129-130

Respiratory disorders in RA, 48-49
 mortality from, 58, 59
 respiratory distress, 40

Rest, in treatment of RA, 102, 105

RF. See *Rheumatoid factor (RF)*.

Rheumatoid arthritis (RA) overview, 13-28
 classification of disease activity, 109-113, 110t
 aggressive RA, 110-111, 110t
 slowly progressive RA, 109-110, 110t
 etiology, 19-20
 immunogenetics, 20-21
 immunopathogenesis, 21-25
 pathology, 14-19
 societal impact, 13-14

Rheumatoid factor (RF), 17, 41
 correlation with rheumatoid nodules, 44
 correlation with rheumatoid vasculitis, 44-45
 correlation with Sjogren's syndrome, 47
 in diagnosis of RA, 65
 immune complexes with, 24
 laboratory testing, 73-74
 in pathogenesis of RA, 17, 21
 as prognostic factor, 59, 60t, 84, 93, 94t, 108, 109
 as risk factor for RA, 20
 in slowly progressive vs aggressive RA, 110t
 "Rheumatoid lung," 48-49

Rheumatoid nodules, 19, 34-35, 36, 42-44, 42
 diagnosis of, 44
 in diagnosis of RA, 65
 olecranon nodule, 34, 36, 42-43
 as prognostic factor, 60t
 in slowly progressive vs aggressive RA, 110t
 treatment of, 44
 worsening with MTX, 44

Rheumatoid variants, 51-54
 adult-onset Still's disease (AOSD), 53-54
 elderly-onset RA, 52
 palindromic rheumatism, 51-52
 polyarticular juvenile arthritis, 52-53
 undifferentiated polyarthritis, 51

Rheumatoid vasculitis, 19, 44-46, 59

Rheumatologists. See also *Early arthritis clinic*.
 interactions with PCP, 111, 112
 practice remodeling for early RA referrals, 96, 309-316
 referrals to, 92-94, 93t
 delays in, 299-301, 300t
 early referrals, 107-108, 303, 304t
 facilitated referrals, 301-302, 303-309
 treatment plan, 106, 145

Rifampin, 211

Risk factors for RA, 20-21

Rituximab, 24-25, 176, 263-272
 approved uses
 B-cell non-Hodgkin's lymphoma, 263
 RA, 265
 use with MTX, 271
 biochemical composition, 263
 clinical efficacy, 265-269, 266, 268, 270
 DANCER trial, 267-269, 268
 REFLEX trial, 269, 270
 combination therapy, 163

- Rituximab (*continued*)
 dosage and administration, 271-272
 indications for, 179, 265
 mechanism of action, 263-264, 267
 safety and tolerability, 268-271
 infections, 270-271
 infusion reactions, 269-270
 progressive multifocal leukoencephalopathy (PML), 270-271
 use in other autoimmune diseases, 272
- Rofecoxib, 123, 124, 125-127. See also *COX-1 and COX-2 inhibitors*.
 APPROVE trial, 126
 VIGOR trial, 126
- Rose bengal test, 47
- Rubella virus, 20
- Safety concerns. See *specific treatments*.
- Salagen (pilocarpine), 47
- Salsalate (Disalcid), 118t, 123
- Schirmer's test, 46-47
- Scleritis, 47-48
- Scleroderma, 158
- Screening of early arthritis patients
 internet screening, 311-316
 prescreening, 312, 314t-315t
 rapid screening patients, 311-312
 screening requirements for facilitated referrals, 305-308, 306t-307t
 telephone screening, 312-313
- SDAI. See *Simplified Disease Activity Index (SDAI)*.
- Serious infectious events (SIEs). See *Infections*.
- Serositis, mortality risk and, 59
- Sex hormones, 31
- Shared epitopes, 21, 24
 CCP antibodies and, 75
 as prognostic factor, 61t, 77, 93, 109
- Simplified Disease Activity Index (SDAI), 325, 325t
- Sjogren's syndrome (keratoconjunctivitis sicca), 46-47
 positive rheumatoid factor (RF) in, 73, 74
 rituximab use in, 272
- Skin cancers, 30
- Slowly progressive RA, 109-110, 110t
 corticosteroid treatment for, 135
 DMARDs for, 110, 144, 152
- Smoking
 as prognostic factor in RA, 61t
 remission rates and, 56
 as risk factor for RA, 20
- Societal impact of RA, 13-14
- Socioeconomic status, as prognostic factor, 109
- Splinting, 102
- Sporotrichosis, 211
- SS-A and SS-B antibodies, 46
- SSZ. See *Sulfasalazine (SSZ)*.
- Steroids, 106, 135-142. See also *Corticosteroids*.
 withdrawal syndrome, 136
- Still-Chauffard variant, 31
- Streptococci*, 20
- Subluxation of joints, 39, 40
- Substance P, 116
- Sulfasalazine (SSZ), 155-156. See also *Disease-modifying antirheumatic drugs (DMARDs)*.
 adverse events, 146t, 155
 for aggressive RA, 111
 combination therapy
 BeST study, 228-231, 230
 COBRA trial, 89-90, 90-92, 91, 138, 155-156, 164-167, 165-166
 in early RA, 120, 155-156
 mechanism of action, 155
 monotherapy vs combined therapy, 90-92, 91, 138, 156, 167-168
 safety monitoring, 146t, 155
 for slowly progressive RA, 110
 toxicities, 146t, 155
- Sulindac (Clinoril), 119t
- Swan neck deformity, 34, 35, 40, 41
- Symmetric joint distribution of RA, 31, 65
- Synovial fluid, 19
 laboratory analysis of, 75-76
- Synovial membrane, normal vs RA, 15-16, 15
- Synoviocytes, in RA pathogenesis, 15-16, 19, 22
- Synovitis, 16-19, 32, 108-109
 intraarticular corticosteroids for, 140-141
 relative inactivity possible, 45
 tenosynovitis, 33, 34
- Synovium, pathology in RA, 14-19
- Systemic amyloidosis, 50
- Systemic inflammatory symptoms, 13
- T-cell co-stimulatory pathway blockade, 175, 275-291
 abatacept (Orencia), 277-289
 dosage and administration, 288-289, 288t
 indications for, 179, 277
 mechanism of action, 277-278, 278
 pharmacology, 278-279
 safety, 283-288

T-cell co-stimulatory pathway blockade (*continued*)

agents under development, 289

alefacept (Amevive), 289

anti-CD80/86, 289

ICOS, 289

IDEC-114, 289

T cell activation process, 275-276, 276

T cells. See also *T-cell co-stimulatory pathway blockade*.

activation process, 275-276, 276

CD4+ helper T cells, 16, 23

CD8+ T cells, 19

cell surface antigens, 16

monoclonal antibodies to, 175

oligoclonal expansion of, 23-24

in pathogenesis of RA, 16-17, 21-23, 22, 275

within rheumatoid synovium, 16

Tachyphylaxis, 116

Tarsal involvement in RA, 38

TEMPO trial, 151, 237-240, 239t

Tenosynovitis, 33, 34

Tetracycline, 143, 161-162

Therapeutic pyramid paradigm, 105-106

Throat pain, 39-40

Thrombocytopenia, 217

Thrombocytosis, 50, 76

TICORA (Tight Control of RA) trial, 59-62, 322-323

Tight Control of RA (TICORA) trial, 59-62, 322-323

TNF (tumor necrosis factor), 23, 176, 177. See also *TNF-blocking therapies*.

binding properties, 199-200

biological actions, 198-200

cellular production of, 198

converting enzyme (TACE), 198-199

mast cell secretion of, 18

mononuclear cell migration and, 25, 177

in pathogenesis of RA, 18, 19, 25, 197, 199-200

receptors, 197, 199-200

in rheumatoid joint, 176, 177

synergistic effect with IL-1, 186

TNF α , 18, 198-200

soluble (sTNF α), 199, 200-201

transmembrane (mTNF α), 199, 200-201

TNF β (lymphotoxin), 199

TNF-blocking therapies, 197-262

adalimumab (Humira), 244-257

clinical efficacy in RA, 246-249, 247-249

indications and dosing, 198t, 245

TNF-blocking therapies, adalimumab (Humira) (*continued*)

pharmacology, 245-246

safety in RA, 254-257, 255t

use in early RA, 249-251, 250

use in elderly patients, 251-253

approved uses

early RA, 179, 197, 198, 198t, 201

other inflammatory disorders, 197, 198t, 201

RA, 179, 197, 198, 198t, 201

biologic effects of, 199-201, 199t

clinical trials

ARMADA trial, 151

ATTRACT trial, 151

numbers of patients in, 202-203

PREMIER trial, 151

combination therapy, 150, 151, 163

durability of, 203, 204

efficacy for other inflammatory disorders, 197

efficacy for RA, 197-198

etanercept (Enbrel), 234-244

clinical efficacy in RA, 235-240, 237-238, 239t

indications and dosing, 179-180, 198t, 234

pharmacology, 235

safety in RA, 242-244, 243t

indications for/use in RA, 178-179, 198t, 201-202

infliximab (Remicade), 220-234

clinical efficacy in RA, 222-224, 225t, 226

indications and dosing, 179, 198t, 221-222

pharmacology, 222

safety in RA, 231-234, 232t

use in early RA, 179, 226-231

mechanism of action, 198-201, 199t

new inhibitors under development, 294-295

certolizumab pegol, 201, 294

golimumab, 294

NF-kB (nuclear factor kappa B), 294

p38 MAP kinases, 294

signaling/small molecules, 294-295

for rheumatoid nodules, 44

safety concerns, 202-219

anaphylactic reactions, 205

autoimmune responses, 213-216

compared with DMARDs, 203

congestive heart failure (CHF), 217

cytopenias, 217-218

demyelinating syndromes, 216

drug-induced lupus, 214-216, 215t

- TNF-blocking therapies, safety concerns (*continued*)
- hepatotoxicity, 218
 - infections, 206-207
 - infusion reactions/injection site reactions, 204-206, 205
 - neoplasia and lymphoma, 212-213
 - opportunistic infections, 211
 - pregnancy and lactation, 218-219
 - tuberculosis, 209-211
 - safety monitoring, 219-220
 - for scleritis and episcleritis, 48
 - use in early RA, 179, 240-241, 241-242
- TNF inhibitors. See *TNF-blocking therapies*.
- Tobacco use, as risk factor for RA, 20
- Tocilizumab, 293
- Toe deformities, 35, 38
- Tolectin (tolmetin), 119t
- Toll-like receptors, 296
- Tolmetin (Tolectin), 119t
- Topical analgesia, 116
- Toxoplasma*, 256
- Tramadol, 115
- Transforming growth factor (TGF) α , 25
- Transforming growth factor (TGF) β , 18, 25
- Trazodone, 115
- Treatment of RA. See also *specific drugs and treatments*.
- ACR treatment algorithm, 112
 - early aggressive treatment, 106
 - follow-up and reassessment, 109, 111, 112
 - initial choice of therapy, 92, 106, 108-109
 - multidisciplinary approach to, 99
 - nonpharmacologic treatment, 99-103
 - pain treatments. See *Pain treatments*.
 - pharmacotherapy, as new paradigm for early RA, 105-114
 - therapeutic pyramid paradigm, 105-106
- Tricyclic antidepressants, for pain, 115
- Trilisate (choline magnesium salicylate), 118t, 123
- Tryptase, mast cell secretion of, 18
- Tuberculin skin test (PPD), 210-211, 220
- Tuberculosis, TNF-blocking therapies and, 209-211
 - adalimumab, 255t
 - etanercept, 243-244, 243t
 - infliximab, 232t
- Tumor necrosis factor (TNF). See *TNF (tumor necrosis factor)*.
- Tumor necrosis factor (TNF) inhibitors. See *TNF-blocking therapies*.
- Twin studies, 20
- UA. See *Undifferentiated arthritis (UA)*.
- Ulcerative colitis, infliximab approved for, 198t, 221
- Ulnar drift, 34, 35, 40, 42
- Ultrasonography, 78-79
- Undifferentiated arthritis (UA), 84-85
 - PROMPT trial (methotrexate), 152
 - treatment of, 108
- Upper extremity
 - involvement in gout, 69
 - involvement in RA, 35-36
- Valdecoxib, 123, 127. See also *COX-1 and COX-2 inhibitors*.
- Variant disorders, 51-54
- Vascular involvement in RA. See *Rheumatoid vasculitis*.
- Vasculitis
 - pulse corticosteroid therapy for, 141
 - rheumatoid, 19, 44-46, 59
 - rituximab use in, 272
- Very early RA (VERA), treatment and outcomes, 83-84, 83t
- Very late activation antigen 4 (VLA-4), 23
- VIGOR (Vioxx GI clinical Outcomes Research) trial, 126
- Vioxx. See *Rofecoxib*.
- Viruses, 19-20
- Vocational rehabilitation, 103
- Voltaren/Voltaren XR (diclofenac), 118t, 120
- Warfarin, COX-inhibitor use and, 124, 125
- Warmth, as clinical sign, 32, 65
- Websites for RA patients, 101t
- Window of opportunity, 82-85, 83t
- Work disability, 13-14
- Wrist joints, 32, 33, 34
 - bent-fork deformity, 40, 43
- Yersinia*, 20
- Zeta deformity, 40, 42

